MODERATOR
:
SPEAKER
(S):
Larry Greenbaum, MD, PhD, Marcus Professor of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta
Richard Smith, MD, Director, Iowa Institute of Human Genetics, The University of Iowa
Description
Atypical hemolytic uremic syndrome (aHUS) is a rare familial disorder with a poor clinical prognosis including death, end-stage renal failure and graft loss following renal transplantation. Recent genetic studies have identified mutations in several proteins related to complement regulation as risk factors for aHUS. This session will focus on our current understanding of the role of complement in aHUS, the genetic basis for defects in complement regulation in aHUS and as new therapeutic strategies for treating patients with aHUS.
-
Discuss the clinical presentation and pathophysiology of atypical hemolytic uremic syndrome (HUS).
-
Discuss the role of apheresis and new therapies in the treatment of atypical HUS.
-
Name at least two protein defects associated with the development of atypical HUS.
CE Category | CE Value |
---|
California Clinical Laboratory Personnel |
1.5 |
California Nurse |
1.8 |
Florida Laboratory Personnel |
1.8 |
General Attendee |
1.5 |
Physician |
1.5 |
Please note: Continuing education (CE) credit is available for online offerings only. Individuals that purchase CD-ROMs will not receive CE credit for the programs they view.